Marcus M. Schittenhelm
Impact in
- Hematology top 1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 24
- Acute Myeloid Leukemia Research 16
- Chronic Myeloid Leukemia Treatments 14
- Genetics 10
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Michael C. HeinrichCarsten BokemeyerKerstin Maria Kampa-SchittenhelmDiana GriffithSharon ShiragaFriedemann HoneckerKonstanze DöhnerFrancis Y. Lee
- Journals
- Blood (13 papers)Cancer Research (3 papers)British Journal of Haematology (2 papers)Cell Death and Disease (2 papers)BMC Cancer (2 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Marcus M. Schittenhelm
40 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 81
- Hematology 767
- Genetics 358
- Oncology 362
- Gastroenterology 71
- Immunology 252
Countries citing papers authored by Marcus M. Schittenhelm
This map shows the geographic impact of Marcus M. Schittenhelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus M. Schittenhelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus M. Schittenhelm more than expected).
Fields of papers citing papers by Marcus M. Schittenhelm
This network shows the impact of papers produced by Marcus M. Schittenhelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus M. Schittenhelm. The network helps show where Marcus M. Schittenhelm may publish in the future.
Co-authors
The 25 scholars most cited alongside Marcus M. Schittenhelm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 0 | |
| 7 | 2021 | 3 | |
| 8 | 2021 | 4 | |
| 9 | 2020 | 11 | |
| 10 | 2019 | 13 | |
| 11 | 2013 | 49 | |
| 12 | 2013 | 18 | |
| 13 | 2013 | 100 | |
| 14 | 2012 | 7 | |
| 15 | Dasatinib and rapamycin synergistically inhibit the proliferation of cells expressing oncogenic KIT kinase via global inhibition of AKT-dependent signaling | 2007 | 1 |
| 16 | 2006 | 79 | |
| 17 | 2006 | 36 | |
| 18 | 2006 | 65 | |
| 19 | 2003 | 103 | |
| 20 | 2000 | 129 |
About Marcus M. Schittenhelm
Marcus M. Schittenhelm is a scholar working on Hematology, Genetics, Oncology, Cancer Research and Rheumatology, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (16 papers), Chronic Myeloid Leukemia Treatments (14 papers), Cancer-related Molecular Pathways (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Mast cells and histamine (6 papers), Eosinophilic Disorders and Syndromes (5 papers), RNA modifications and cancer (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). The work is most often cited by research in Hematology (767 citations), Genetics (358 citations), Oncology (362 citations), Gastroenterology (71 citations) and Immunology (252 citations). Marcus M. Schittenhelm has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Michael C. Heinrich, Carsten Bokemeyer, Kerstin Maria Kampa-Schittenhelm, Diana Griffith, Sharon Shiraga, Friedemann Honecker, Konstanze Döhner, Francis Y. Lee, Brian Druker and Amie S. Corbin. Their work appears in journals such as Blood, Cancer Research, British Journal of Haematology, Cell Death and Disease and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.